13.30 - 15.30
THE M.D. ANDERSON CANCER CENTRE APPROACH TO HEMATOLOGIC MALIGNANCIES Supported by Schering AG, Berlex Oncology
NOVEL TREATMENTS FOR ANAEMIA AND NEUTROPENIA: FROM ENHANCED BIOLOGICAL ACTIVITY TO CLINICAL PRACTICE Supported by Amgen (Europe) AG
MYLOTARG: GEMTUZUMAB OZOGAMICIN, THE FIRST ANTIBODY-TARGET CHEMOTHERAPY FOR ACUTE LEUKEMIA Supported by Wyeth S.p.A.
15.45 - 17.45
MANAGING CML IN THE GLIVEC ERA Supported by Novartis Pharma
THE ROLE OF TRISENOX IN THE MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKAEMIA Supported by Cell Therapeutics (UK) Ltd.
LIVING STRONGER, LIVING LONGER? OPTIMIZING THE MANAGEMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASIA Supported by Ortho Biotech
18.30 - 20.30
NEW OPTIONS IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES Supported by Schering AG
18.00 - 20.30
OPTIMISING CARE IN NHL Supported by F. Hoffmann - La Roche
AVII (NOVOSEVEN) AS A GENERAL HAEMOSTATIC AGENT? Supported by Novo Nordisk
18.00 - 20.00
MYELODYSPLASTIC SYNDROMES - EMERGING THERAPIES Supported by Pharmion Corporation
